On May 10, 2021 Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, reported that Catalyst Clinical Research will enter into a partnership to leverage Calyx’s Medical Imaging solution for their customers’ oncology trials (Press release, Catalyst Clinical Research, MAY 10, 2021, View Source [SID1234579548]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A leading provider of clinical research services, Catalyst Clinical Research’s full-service, niche oncology CRO solution is focused on next-generation cancer therapies. Catalyst Oncology offers skilled management of immuno-oncology and targeted therapies as well as expert oversight of complex study designs to deliver customized clinical research solutions exclusively for the biotech market.
"We see a lot of synergies between Calyx’s expertise in medical imaging, particularly in early phase oncology development, and Catalyst Oncology’s clinical development services for the advancement of new cancer treatments," said Andrew Zupnick, PhD, Vice President of Oncology Drug Development at Catalyst. "We’re pleased to form a relationship through their CRO partnership program and look forward to working together as we help our customers bring novel therapies to cancer patients in need."
The program, "ACTIVATE Solutions for CRO Partners," is designed to provide close alignment between Calyx and its CRO partners. By participating in the ACTIVATE program, Catalyst can better meet the imaging needs of their clients and help accelerate oncology trial execution and data collection, ultimately delivering more customer value.
"Catalyst is at the forefront in delivering customized services that meet the evolving needs and unexpected changes inherent in oncology clinical development," said John Blakeley, Chief Commercial Officer, Calyx. "We’re delighted to welcome them to our partnership network and to support their knowledgeable, experienced team with a proven imaging solution as they execute complex oncology trials for their biotech clients."